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Drug-induced lupus erythematosus is deﬁned as a lupus-like syndrome temporally related to continuous drug exposure which
resolves after discontinuation of the oﬀending drug. Herein, we describe a patient with distinct clinical manifestations of anti-
TNF-associated DILE related to inﬂiximabtherapy. The patient exhibited clinical and laboratory ﬁndings of lupus-like illnesses as
well as ocular disorders, such as episcleritis. The main message is that the symptoms of DILE should not be overlooked, although
sometimes other systematic conditions may underlie them. As a result, it is very important for the clinicians to evaluate the
symptoms of DILE and manage appropriately these cases.
1.Introduction
Drug-induced lupus erythematosus (DILE) is deﬁned as a
lupus-like syndrome (LLS) temporally related to continuous
drug exposure which resolves after discontinuation of the
oﬀending drug. Its incidence has been estimated as up to
10% of systemic lupus erythematosus (SLE) cases [1, 2].
Inﬂiximab is a human monoclonal antitumor necrosis
factor (anti-TNF) agent with a good safety proﬁle. Since the
widespread usage of inﬂiximab for the treatment of rheu-
matoid arthritis (RA), psoriatic arthritis (PsA), spondyloar-
thropathies, and inﬂammatory bowel disease, there have
been reported several case reports of DILE and LLS associ-
ated withthe use ofthis drug.Inductionofautoantibodies in
patients treated with inﬂiximab is also well established [3–6],
but ocular disorders and especially episcleritis are relatively
rare.
Herein, we describe a patient with distinct clinical man-
ifestations of anti-TNF-associated DILE related to inﬂix-
imab therapy. The patient exhibited clinical and laboratory
ﬁndings of lupus-like illnesses as well as ocular disorders.
These symptoms developed while receiving the anti-TNF
therapy and resolved on discontinuation of the oﬀending
drug [6].
2.Case Presentation
A 42-year-old woman with Crohn’s disease was started on
inﬂiximab in 2008 for colitis poorly responsive to conven-
tional therapy. She had prompt and dramatic improvement
in her symptoms and before the initiation of inﬂiximab,
her antinuclear antibodies (ANA) and anti-double-stranded
DNA (dsDNA) were negative. One year later, she presented
with polyarthritis, a rash on her face and chest, profound
fatigue, and photosensitivity. Laboratory evaluation revealed
an ANAtitre of1:160,a positive testfor anti-dsDNAand for
antihistone antibodies, while antiextractable nuclear antigen
antibodies (ENA) were negative. The patient also presented
mild thrombocytopenia and elevated CRP, whereas all other
laboratory ﬁndings were normal. The diagnosis of DILE
w a sc o n ﬁ r m e da n ds h es t o p p e dt aking inﬂiximab. She also2 Case Reports in Medicine
received 30mg/day prednisone for four weeks. Her symp-
toms gradually improved six weeks after discontinuation of
inﬂiximab and treatment with prednisone.
Five months later, she resumed inﬂiximab because of
worsening colitis and joint pain. She developed again skin
lesions, polyarthritis, and pain on eye movements, asso-
ciated with acute onset redness in one eye two months
after restarting inﬂiximab. Serologic testing was positive for
ANA, antihistone, and dsDNA antibodies, but remained
negative for ENA. In addition to this, the patient underwent
a thorough ophthalmologic examination, which revealed
episcleritis. Therefore, the patient was diagnosed as a case of
DILE with ocular manifestations. After stopping inﬂiximab,
the lesions faded out overthe following four weeks, serologic
testing normalized, and her symptoms resolved, so did the
episcleritis. Writteninformed consentwas obtained from the
patient.
3.Discussion
As anti-TNF therapy, especially inﬂiximab or adalimumab,
becomes more widely used for a variety of diseases, the diag-
nosis and management for DILE will become an increasingly
important challenge [3–7]. Recognition of DILE in patients
receiving anti-TNF therapy can be especially diﬃcult due
to the symptoms of their underlying diseases. There are
currently no standard diagnostic criteria for DILE and the
pathomechanisms are still unclear. The range of symptoms
which are typically present and could be employed as
diagnostic criteria is conﬁned to four (arthritis, serositis,
antinuclear, and antihistone antibodies); in addition the
symptoms must have begun after initiation of the treatment
withadrugand mustresolve ondiscontinuationofthatdrug
treatment [2]. Furthermore,othersymptoms may exist, such
as rash, polyarthralgias, myalgias, fever, pericarditis, or pho-
tosensitivity. Central nervous system and renal involvement
are usually rare [5–7]. Our patient not only had the classic
symptoms of DILE but also suﬀered from episcleritis, which
is a rare immune-mediated clinical manifestation.
Scleritisandepiscleritisarewell-established ocularsymp-
tomsofsystematiclupuserythematosus[8–11].Turgeonand
Slamovits had described a case of scleritis in a patient using
procainamide as a part of a drug-induced lupus syndrome
[12]. Interestingly enough, inﬂiximab has been used for
the treatment of uveitis or scleritis [13–15]. In our case,
episcleritiswas notconsidered to be an isolated adverse eﬀect
of inﬂiximab, but an ocular manifestation of DILE due to
inﬂiximab.
In addition, ocular manifestations of inﬂammatory bow-
el disease are not frequent, occurring in less than 10% of
cases [16]. The most common ocular ﬁndings are found
to be conjunctivitis, blepharitis, uveitis, episcleritis, cataract,
choroiditis, retinal vasculitis, and optic neuritis [17, 18].
Our patient suﬀered from Crohn’s disease, but she never
complained of ophthalmological symptoms. Noticeably, she
developed episcleritis when she was under inﬂiximab treat-
ment, having in parallel other DILE manifestations, and
not while an active symptom period of Crohn’s disease.
Nevertheless, this conceptualoverlap between extraintestinal
manifestations of Crohn’s disease and DILE should be taken
into account at the interpretation of this case.
Laboratory abnormalities in anti-TNF DILE reported
cases diﬀer from classic DILE. Positive anti-dsDNA occurs
frequently in anti-TNF-induced DILE compared with classic
DILE. Antihistone antibodies are described in classic DILE
m o r eo f t e nt h a ni na n t i - T N F aD I L E( 9 5 %v e r s u s5 7 % ,
respectively) [1, 5, 6]. In our case, the patient had positive
anti-dsDNA, ANA, and antihistone antibodies; however,
ENA were negative.
Discontinuation of the treatment remains the main ther-
apeutic intervention and most of patients experience a clin-
ical improvement 6–12 weeks after the suppression of the
implicated drug [5, 6], although there are cases that needed
three weeks [7] to be improved. Our patient presented a
clinical improvement after four weeks of treatment cessa-
tion.
The most astonishing feature of this case report is that
anti-TNF DILE can be associated with ocular disorders, such
as episcleritis. Therefore, the symptoms of DILE should not
be overlooked, although sometimes other systematic condi-
tions may underlie them. As a result, it is very important for
the clinicians to evaluate the symptoms of DILE and manage
appropriately these cases.
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